Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 129 publications
Proteomic analysis reveals early pathological defects in corticospinal motor neurons of a spastin model of hereditary spastic paraplegia, which are improved by NU-9 treatment.
Journal: Neurobiology of disease
Published: April 28, 2026
Inactivation of ornithine aminotransferase by (1R,4S)-4-Amino-3-(trifluoromethyl)cyclopent-2-ene-1-carboxylic acid via a stable quinonoid intermediate.
Journal: Medicinal chemistry research : an international journal for rapid communications on design and mechanisms of action of biologically active agents
Published: February 11, 2026
Dynamic tail amine interactions drive isoform selectivity for potent human neuronal nitric oxide synthase inhibitors.
Journal: Medicinal chemistry research : an international journal for rapid communications on design and mechanisms of action of biologically active agents
Published: February 09, 2026
Enhancement of Potency and Selectivity of 2-Aminoquinoline-Based Human Neuronal Nitric Oxide Synthase Inhibitors.
Journal: Journal of medicinal chemistry
Published: February 04, 2026
Potent, Selective, and Brain Penetrant Ether-Linked 2-Aminopyridine Inhibitors of Human Neuronal Nitric Oxide Synthase with Excellent Oral Bioavailability.
Journal: Journal of medicinal chemistry
Published: February 03, 2026
New Inhibitors of Neuronal Nitric Oxide Synthase for the Treatment of Melanoma.
Journal: Journal of medicinal chemistry
Published: January 30, 2026
A newly designed GABA-AT inactivator, (S)-MeCPP-115, suppresses paclitaxel-induced neuropathic pain in mice.
Journal: bioRxiv : the preprint server for biology
Published: November 24, 2025
Identification of a glia-associated amyloid β oligomer subtype and the rescue from reactive astrogliosis by inhibitor NU-9.
Journal: Alzheimer's & dementia : the journal of the Alzheimer's Association
Published: August 14, 2025
Modifications of NU-9, a potent protein aggregation inhibitor. Properties and activity in a cellular model of amyotrophic lateral sclerosis.
Journal: Bioorganic chemistry
Published: July 20, 2025
Targeting Neuronal Nitric Oxide Synthase (nNOS) as a Novel Approach to Enhancing the Anti-Melanoma Activity of Immune Checkpoint Inhibitors.
Journal: Pharmaceutics
Published: April 09, 2025
Inhibition of amyloid beta oligomer accumulation by NU-9: A unifying mechanism for the treatment of neurodegenerative diseases.
Journal: Proceedings of the National Academy of Sciences of the United States of America
Published: March 03, 2025
Last Updated: 09/26/2026